<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982186</url>
  </required_header>
  <id_info>
    <org_study_id>CR108608</org_study_id>
    <secondary_id>2019-000622-22</secondary_id>
    <secondary_id>73763989HPB2001</secondary_id>
    <nct_id>NCT03982186</nct_id>
  </id_info>
  <brief_title>A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection</brief_title>
  <acronym>REEF-1</acronym>
  <official_title>A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the dose-response relationship for antiviral
      activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the
      efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of
      JNJ-56136379+NA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV) is a small deoxyribonucleic acid virus that specifically infects the
      human liver. The acute phase of infection is either followed by an immune controlled state or
      progresses to chronic hepatitis B. The worldwide estimated prevalence of chronic HBV
      infection is about 292 million people affected. Hepatitis B surface antigen (HBsAg)
      seroclearance is currently considered to be associated with the most thorough suppression of
      HBV replication (termed functional cure). With current available NA treatment strategies,
      rate of HBsAg seroclearance remains very low (around 3 percent [%]) even under long-term
      treatment. Also, with the persistently high global prevalence of HBV-associated mortality,
      there is a medical need for more effective finite treatment options that lead to sustained
      HBsAg seroclearance. JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous
      injection designed to treat chronic HBV infection via ribonucleic acid interference
      mechanism. JNJ-56136379 is an orally administered capsid assembly modulator that is being
      developed for the treatment of chronic HBV infection. The aim of the study is to evaluate
      efficacy as measured by proportion of participants who completed 48-week study intervention
      and qualified for stopping NA treatment at Week 48. The study includes: Screening phase (4
      weeks), Double-blind study intervention phase (from Day 1 up to Week 48), and Follow-up phase
      (48 weeks after end of investigational intervention with a maximum duration of 96 weeks). The
      duration of individual study participation will be between 100 and 150 weeks. Safety and
      tolerability (including adverse events [AEs] and Serious AEs, laboratory assessments,
      electrocardiogram [ECG], vital signs, physical examination), efficacy (including HBsAg
      seroclearance), and pharmacokinetics will be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Meeting the Nucleos(t)ide Analog (NA) Treatment Completion Criteria at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants meeting the NA treatment completion criteria at week 48 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE) and Serious Adverse Events (SAE) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to follow-up (maximum up to 150 weeks)</time_frame>
    <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormalities in Clinical Laboratory Tests, 12-Lead Electrocardiogram (ECG), and Vital Signs</measure>
    <time_frame>Up to follow-up (maximum up to 150 weeks)</time_frame>
    <description>Number of participants with abnormalities in clinical laboratory tests, 12-lead ECG, and vital signs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroclearance After Completion of all Study Intervention</measure>
    <time_frame>Week 72 and Week 96</time_frame>
    <description>Percentage of participants with hepatitis B surface antigen (HBsAg) seroclearance after completion of all study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA less than (&lt;) Lower Limit of Quantification (LLOQ) After Completion of all Study Intervention</measure>
    <time_frame>Week 72 and Week 96</time_frame>
    <description>Percentage participants with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) &lt;LLOQ after completion of all study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the NA Treatment Completion Criteria During Follow-up</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Percentage of participants meeting the NA treatment completion criteria during follow-up will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroclearance After Completion of NA Treatment at any Time During Follow-up</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants with HBsAg seroclearance after completion of NA treatment at any time during follow-up will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring NA Re-treatment During Follow-up</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants requiring NA re-treatment during follow-up will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Relapse</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants with relapse will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with (Sustained) Reduction, Suppression, and/or Seroclearance Considering Single and Multiple Markers</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with (sustained) reduction, suppression, and/or seroclearance considering single and multiple markers (such as hepatitis B surface antigen [HBsAg], hepatitis B e antigen [HBeAg], HBV DNA and alanine aminotransferase [ALT]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroconversion</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants with HBsAg seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBeAg Seroconversion</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants with HBeAg seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HBsAg Levels</measure>
    <time_frame>Baseline up to follow up (up to Week 150)</time_frame>
    <description>Change from baseline in HBsAg levels will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HBeAg Levels</measure>
    <time_frame>Baseline up to follow up (up to Week 150)</time_frame>
    <description>Change from baseline in HBeAg levels will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HBV DNA Levels</measure>
    <time_frame>Baseline up to follow up (up to Week 150)</time_frame>
    <description>Change from baseline in HBV DNA levels will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve HBsAg Seroclearance</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Time to achieve HBsAg seroclearance will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve HBeAg Seroclearance</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Time to achieve HBeAg seroclearance will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &lt;100 IU/mL or &gt;1 log10 IU/mL Reduction in HBsAg From Baseline</measure>
    <time_frame>Baseline up to Week 150</time_frame>
    <description>Percentage of participants with less than (&lt;) 100 international units per milliliter (IU/mL) or greater than (&gt;) 1 log10 IU/mL reduction in HBsAg from baseline will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HBeAg-positive Participants with HBeAg Levels</measure>
    <time_frame>Baseline up to Week 150</time_frame>
    <description>Percentage of HBeAg-positive participants with HBeAg levels will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ALT Decrease and Normalization</measure>
    <time_frame>Up to follow-up (maximum up to 150 weeks)</time_frame>
    <description>Percentage of participants with alanine aminotransferase (ALT) decrease and normalization will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants with virologic breakthrough defined as confirmed on-treatment HBV DNA increase by &gt;1 log10 IU/mL from nadir level or confirmed on treatment level &gt;200 IU/mL in participants who had HBV DNA level below &lt;LLOQ of the HBV DNA assay will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable HBV DNA Levels After Re-start of NA Treatment During Follow-up</measure>
    <time_frame>Up to 150 weeks</time_frame>
    <description>Percentage of participants who reach HBV DNA undetectability after re-start of NA treatment during follow-up will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over the Dosing Interval (tau) at Steady-state (AUCtau,ss) of JNJ-73763989</measure>
    <time_frame>Days 1, 29, 85, 169 and 337</time_frame>
    <description>The AUC (tau,ss) is the area under the plasma concentration time curve observed during a dosing interval (tau) at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over the Dosing Interval (tau) at Steady-state (AUCtau,ss) of JNJ-56136379</measure>
    <time_frame>Days 1, 29, 85, 169 and 337</time_frame>
    <description>The AUC (tau,ss) is the area under the plasma concentration time curve observed during a dosing interval (tau) at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over the Dosing Interval (tau) at Steady-state (AUCtau,ss) of NA</measure>
    <time_frame>Days 1, 29, 85, 169 and 337</time_frame>
    <description>The AUC (tau,ss) is the area under the plasma concentration time curve observed during a dosing interval (tau) at steady state.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">471</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: JNJ-73763989 (high dose) + Placebo + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: JNJ-73763989 (medium dose) + Placebo + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: JNJ-73763989 (low dose) + Placebo + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Placebo + JNJ-56136379 + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 (Control): Placebo + Placebo + NA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.</description>
    <arm_group_label>Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 (high dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 (medium dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 4: JNJ-73763989 (low dose) + Placebo + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for JNJ-73763989</intervention_name>
    <description>Placebo for JNJ-73763989 will be administered as subcutaneous injection.</description>
    <arm_group_label>Arm 5: Placebo + JNJ-56136379 + NA</arm_group_label>
    <arm_group_label>Arm 6 (Control): Placebo + Placebo + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>JNJ-56136379 tablets will be administered orally.</description>
    <arm_group_label>Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA</arm_group_label>
    <arm_group_label>Arm 5: Placebo + JNJ-56136379 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for JNJ-56136379</intervention_name>
    <description>Placebo for JNJ-56136379 tablets will be administered orally.</description>
    <arm_group_label>Arm 2: JNJ-73763989 (high dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 (medium dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 4: JNJ-73763989 (low dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 6 (Control): Placebo + Placebo + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide Analog (NA)</intervention_name>
    <description>NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.</description>
    <arm_group_label>Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 (high dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 (medium dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 4: JNJ-73763989 (low dose) + Placebo + NA</arm_group_label>
    <arm_group_label>Arm 5: Placebo + JNJ-56136379 + NA</arm_group_label>
    <arm_group_label>Arm 6 (Control): Placebo + Placebo + NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable based on physical examination, medical history, vital signs,
             electrocardiogram (ECG) at screening

          -  Chronic hepatitis B virus (HBV) infection with documentation at least 6 months prior
             to screening

          -  Hepatitis B surface antigen (HBsAg) greater than (&gt;) 100 International Units per
             Milliliter (IU/mL) at screening

          -  Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2),
             extremes included

          -  Highly effective contraceptive measures in place for female participants of
             childbearing potential or male participants with female partners of childbearing
             potential

          -  Liver fibrosis stage 0-2 (Metavir) or Fibroscan less than (&lt;) 9 Kilopascal (kPa) at
             screening

        Exclusion Criteria:

          -  Evidence of infection with hepatitis A, C, D or E virus infection or evidence of human
             immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening

          -  History or evidence of clinical signs/symptoms of hepatic decompensation including but
             not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal
             varices or any laboratory abnormalities indicating a reduced liver function as defined
             in the protocol

          -  Evidence of liver disease of non-HBV etiology

          -  Signs of hepatocellular carcinoma (HCC)

          -  Significant laboratory abnormalities as defined in the protocol at screening

          -  Participants with a history of malignancy within 5 years before screening

          -  Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol

          -  History of or current cardiac arrhythmia or history or clinical evidence of
             significant or unstable cardiac disease

          -  Participants with any current or previous illness for which, in the opinion of the
             investigator and/or sponsor, participation would not be in the best interest of the
             participant

          -  History of or current clinically significant skin disease or drug rash

          -  Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 and
             JNJ 6379 or their excipients or excipients of the placebo content

          -  Contraindications to the use of entecavir (ETV), tenofovir disoproxil fumarate (TDF),
             or tenofovir alafenamide (TAF) per local prescribing information

          -  Participants who have taken any therapies disallowed per protocol

          -  Female participants who are pregnant, or breast-feeding, or planning to become
             pregnant while enrolled in this study or within 90 days after the last dose of study
             intervention

          -  Male participants who plan to father a child while enrolled

          -  Participants who had or planned major surgery, (example, requiring general anesthesia)
             or who have received an organ transplant

          -  Vulnerable participants (example, incarcerated individuals, individuals under a legal
             protection measure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Office of Franco Felizarta, MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California GI and Liver Center</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.D. Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Hepatology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação De Medicina Tropical Doutor Heitor Vieira Dourado</name>
      <address>
        <city>Manaus</city>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Universidade Federal da Bahia</name>
      <address>
        <city>Salvador</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Faculty of Medicine &amp; Dentistry</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute (G.I.R.I.)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RESEARCH SITE s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>32600</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLIN MED s.r.o</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Praha</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPIMED GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICH Study Center GmbH &amp; Co. KG</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena, Ospedale di Baggiovara</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma 'La Sapienza' - Umberto I Policlinico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical and Dental University</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui-ken Saiseikai Hospital</name>
      <address>
        <city>Fukui City</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuyama City Hospital</name>
      <address>
        <city>Fukuyama</city>
        <zip>721-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Kagawa</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashino Red Cross Hospital</name>
      <address>
        <city>Musashino</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah</name>
      <address>
        <city>Alor Setar</city>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University Sains Malaysia</name>
      <address>
        <city>Kota Bharu</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59120</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zakazny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wroclawskie Centrum Zdrowia</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural State Medical University</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center For AIDS And Infectious Diseases Treatment And Prophylaxis</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of the Modern Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>121170</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center 'SibNovoMed' LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Center for AIDS and Infectious Diseases Treatment and Prophylaxis</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Infectious Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Infectious Diseases Hospital n. a. S.P. Botkin</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Company 'Hepatolog' Ltd</name>
      <address>
        <city>Samara</city>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta De Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10500</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Of Songkla University</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>6230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>6800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical of Faculty, Department of Gastroenterology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's, University of London and St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

